openPR Logo
Press release

Allergic Conjunctivitis Pipeline Assessment 2024 | Clinical Trials, FDA Approvals, Therapies, Companies

07-31-2024 10:58 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Allergic Conjunctivitis Pipeline Segment

Allergic Conjunctivitis Pipeline Segment

As per DelveInsight's assessment, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Allergic Conjunctivitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
The Allergic Conjunctivitis Pipeline report 2024 [https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kpr] embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Allergic Conjunctivitis Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging therapies for the treatment of Allergic Conjunctivitis and the aggregate therapies developed by major pharma companies.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Allergic Conjunctivitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

[https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kpr]

The report covers the emerging products under different phases of clinical development like -

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Allergic Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Inhalation

Inhalation/Intravenous/Oral

Intranasal

Intravenous

Intravenous/ Subcutaneous

Oral

Oral/intranasal/subcutaneous

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

Antibody

Antisense oligonucleotides

Immunotherapy

Monoclonal antibody

Peptides

Protein

Recombinant protein

Small molecule

Stem Cell

Vaccine

Learn How the Ongoing Clinical & Commercial Activities will Affect the Allergic Conjunctivitis Therapeutic Segment @

https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kpr]

Allergic Conjunctivitis Therapeutics Landscape [https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kpr]

There are approx. 22+ key companies developing therapies for Allergic Conjunctivitis. Currently, Aldeyra Therapeutics is leading the therapeutics market with its Allergic Conjunctivitis drug candidates in the most advanced stage of clinical development.

[https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kpr] Include:

Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina Espana S.A, Biomay AG, and others.

Allergic Conjunctivitis Emerging and Marketed Drugs Covered in the Report Include:

Reproxalap: Aldeyra Therapeutics

VSJ-110: Vanda Pharmaceuticals

And Many More

Table of Contents

1. Report Introduction

2. Executive Summary

3. Allergic Conjunctivitis Current Treatment Patterns

4. Allergic Conjunctivitis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Allergic Conjunctivitis Late Stage Products (Phase-III)

7. Allergic Conjunctivitis Mid-Stage Products (Phase-II)

8. Allergic Conjunctivitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Allergic Conjunctivitis Discontinued Products

13. Allergic Conjunctivitis Product Profiles

14. Key Companies in the Allergic Conjunctivitis Market

15. Key Products in the Allergic Conjunctivitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Allergic Conjunctivitis Unmet Needs

18. Allergic Conjunctivitis Future Perspectives

19. Allergic Conjunctivitis Analyst Review

20. Appendix

21. Report Methodology

Request for a free sample report @

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-conjunctivitis-pipeline-assessment-2024-clinical-trials-fda-approvals-therapies-companies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Allergic Conjunctivitis Pipeline Assessment 2024 | Clinical Trials, FDA Approvals, Therapies, Companies here

News-ID: 3606182 • Views:

More Releases from ABNewswire

Understanding Magnetic Switches: Types, Working Principles, and Applications
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications. What is a Magnetic Switch? A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed
Innovating embedded downlight technology: Leading the global trend of intelligent, efficient and customized lighting
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded
North China Electric Power University Foreign Aid Training Program Visits Yiyuan Tech for Exchange
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives. Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg Upon arrival, the delegation received a warm welcome from company leadership and the reception
Pure Sine Wave Low Frequency Inverter Charger
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current

All 5 Releases


More Releases for Allergic

Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth? Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the
Allergic Conjunctivitis Market Statistics, Growth | Forecast
The new report published by The Business Research Company, titled ""Allergy Conjunctivitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.4 billion in 2023
Anti-Allergic Drugs Market Overview 2030
Anti-allergic drugs represent a pivotal domain in healthcare, providing advanced solutions to alleviate symptoms triggered by allergens. With an ever-growing prevalence of allergies globally, the anti-allergic drugs market is witnessing a significant surge. Valued at USD 26,234 Million in 2021, the market is poised to skyrocket to USD 47,566 Million by 2030, showcasing a robust CAGR of 6.8%. In the United States alone, where allergies affect 40 to 50 million
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892 This latest report researches the industry structure, sales, revenue,
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which